Provided by Tiger Trade Technology Pte. Ltd.

IO Biotech, Inc.

0.1945
+0.00170.88%
Volume:331.35K
Turnover:65.54K
Market Cap:13.99M
PE:-0.15
High:0.2055
Open:0.2000
Low:0.1929
Close:0.1928
52wk High:2.79
52wk Low:0.1402
Shares:71.95M
Float Shares:31.16M
Volume Ratio:0.57
T/O Rate:1.06%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.3356
EPS(LYR):-1.4494
ROE:-240.48%
ROA:-88.58%
PB:15.36
PE(LYR):-0.13

Loading ...

IO Biotech Inc expected to post a loss of 22 cents a share - Earnings Preview

Reuters
·
Mar 13

IO Biotech Faces Nasdaq Delisting Risk Over Market Value Rule

Reuters
·
Feb 14

IO Biotech launches strategic review amid major restructuring

TIPRANKS
·
Jan 31

IO Biotech Inc - Expects One-Time Charges of $2.4 Mln to $2.6 Mln, During Q1 2026 - SEC Filing

THOMSON REUTERS
·
Jan 31

IO Biotech Cuts Workforce Amid Strategic Review

Reuters
·
Jan 30

IO Biotech Inc - Announces Significant Workforce Reduction

THOMSON REUTERS
·
Jan 30

IO Biotech Shares Fall After Piper Sandler Downgrade

MT Newswires Live
·
Jan 27

IO Biotech Cut to Neutral From Overweight by Piper Sandler

Dow Jones
·
Jan 27

Piper Sandler Downgrades IO Biotech to Neutral From Overweight, Adjusts Price Target to $0.50 From $3

MT Newswires Live
·
Jan 26

IO Biotech downgraded to Neutral from Overweight at Piper Sandler

TIPRANKS
·
Jan 24

NASD Most Active Issues

Dow Jones
·
Jan 24

BRIEF-Io Biotech Announces Exploration Of Strategic Alternatives

Reuters
·
Jan 21

IO Biotech announces exploration of strategic alternatives

TIPRANKS
·
Jan 21

IO Biotech Announces Exploration of Strategic Alternatives

THOMSON REUTERS
·
Jan 21

IO Biotech Inc - Evaluating Further Reduction-in-Force to Cut Expenses

THOMSON REUTERS
·
Jan 21

Morgan Stanley Downgrades IO Biotech to Underweight, Price Target is $0.36

MT Newswires Live
·
Jan 08

IO Biotech Faces Nasdaq Delisting Risk Over Minimum Bid Price Compliance

Reuters
·
Dec 20, 2025

IO Biotech Reports Five-Year Survival Data for IO102-IO103 Vaccine in Metastatic Melanoma Trial

Reuters
·
Dec 16, 2025

IO Biotech Announces Publication of Five-Year Clinical Outcomes of Phase 1/2 Trial in Nature Communications

THOMSON REUTERS
·
Dec 16, 2025

IO Biotech Announces Participation in Upcoming December Investor Conferences

GlobeNewswire
·
Nov 26, 2025